LIVE TRACKER · LAST UPDATED OCT 12, 2026
On April 15 the FDA pulled twelve peptides off its do-not-compound list. None of them are legal to compound yet. This page tracks where each one sits, and we update it when anything moves.
Read the full breakdown →REPAIR AND TISSUE
BPC-157
PANEL VOTED YES · NOT ON BULKS LIST
TB-500 (Thymosin Beta-4 fragment)
PANEL VOTED YES · NOT ON BULKS LIST
GHK-Cu (injectable routes)
NOT REVIEWED · CONSULT BY FEB 2027
IMMUNE AND GUT
KPV
PANEL VOTED YES · NOT ON BULKS LIST
LL-37 (Cathelicidin)
NOT REVIEWED · CONSULT BY FEB 2027
BRAIN AND SLEEP
Semax
PANEL VOTED YES · NOT ON BULKS LIST
Dihexa Acetate
NOT REVIEWED · CONSULT BY FEB 2027
DSIP (Emideltide)
ATTENDANCE UNCONFIRMED · NOT ON BULKS LIST
LONGEVITY, GROWTH AND AESTHETICS
Epitalon
PANEL VOTED YES · NOT ON BULKS LIST
MOTs-C
PANEL VOTED YES · NOT ON BULKS LIST
PEG-MGF
NOT REVIEWED · CONSULT BY FEB 2027
Melanotan II
NOT REVIEWED · CONSULT BY FEB 2027
Status per FDA's interim 503A bulks list and the July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting. FDA staff recommended against all seven substances reviewed in July, even where the panel voted yes.
KEY DATES
APR 15, 2026
FDA republishes its interim 503A list and moves all twelve out of Category 2.
JUL 23–24, 2026
Advisory panel votes yes on six. FDA staff recommend against all seven reviewed.
BY FEB 2027
Expected consultation on the five that haven't been reviewed yet.
Free, twice a week. We read the paperwork so you don't have to.
Educational content only. Not medical or legal advice.